New combo therapy shows promise in stomach cancer battle

NCT ID NCT05008783

First seen Nov 19, 2025 · Last updated May 16, 2026 · Updated 20 times

Summary

This study tested whether adding the drug AK104 to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. It involved 610 adults who had not received prior treatment. The goal was to see if the combination improves survival and shrinks tumors compared to chemotherapy alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fudan University Cancer Hospital

    Shanghai, Shanghai Municipality, 200032, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, 350014, China

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, 100143, China

  • The First Affiliated Hospital of Zhejiang University Medical College

    Hangzhou, Zhejiang, 310003, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610044, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, 650118, China

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 20032, China

Conditions

Explore the condition pages connected to this study.